A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

NCT04837508 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Biliary Tract Cancer

Interventions

DRUG: MRG002

Sponsor

Shanghai Miracogen Inc.